HepTcell

About Altimmune

Altimmune leverages its proprietary peptide technology platform to design multi-targeted agonists that address complex metabolic disorders. The company's most advanced program, pemvidutide, has demonstrated promising weight loss and liver fat reduction in clinical studies, positioning it in the competitive but high-value obesity and MASH markets. Altimmune's strategy is to advance pemvidutide through clinical development, potentially seeking partnerships for later-stage trials and commercialization. The company operates as a lean, research-focused organization with key expertise in peptide chemistry and metabolic disease.

Therapeutic Areas